This grant from the National Cancer Institute (NCI) supports the Cancer Target Discovery and Development (CTD2) program. Its primary purpose is to bridge the knowledge gap between extensive molecular characterizations of cancer and the underlying etiology of its development, progression, or metastasis. Specifically, this NCI grant aims to improve understanding of how mutations in cancer-associated genes affect protein activity and the resulting cellular changes within tumors and their microenvironment. It also seeks to identify new molecular targets, elucidate their wiring mechanisms, and overcome innate or acquired resistance to therapies, particularly focusing on clinical resistance linked to tumor heterogeneity. Furthermore, a key goal is to develop efficient strategies for identifying optimal combinations of perturbagens, including immunotherapeutics, to eliminate all cancer cells despite clonal heterogeneity and the surrounding microenvironment.
Opportunity ID: 334676
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-274 |
| Funding Opportunity Title: | Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | 12 |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 12, 2021 |
| Last Updated Date: | Jul 12, 2021 |
| Original Closing Date for Applications: | Oct 06, 2022 |
| Current Closing Date for Applications: | Oct 06, 2022 |
| Archive Date: | Nov 11, 2022 |
| Estimated Total Program Funding: | $12,000,000 |
| Award Ceiling: | $750,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments City or township governments Special district governments Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Independent school districts Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program “Cancer Target Discovery and Development (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis. The primary purpose of CTD2 is to advance the following areas: Improving the understanding of how mutations in cancer-associated genes affect the protein activity (e.g., gain-of-function, loss-of-function, or neomorphic function) within the cellular pathway(s) they are part of and the cellular changes that result within the context of various tumors and the microenvironment; Identifying new molecular targets with the goal to understand their wiring mechanisms and how overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity and their surrounding microenvironment. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-274.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 334676 Full Announcement-PAR-21-274 -> PAR-21-274-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268191 | Sep 06, 2021 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270422 | Nov 18, 2021 | Oct 06, 2022 | View |
Package 1
Mandatory forms
334676 RR_SF424_2_0-2.0.pdf
334676 PHS398_CoverPageSupplement_5_0-5.0.pdf
334676 RR_OtherProjectInfo_1_4-1.4.pdf
334676 PerformanceSite_2_0-2.0.pdf
334676 RR_KeyPersonExpanded_2_0-2.0.pdf
334676 PHS398_ResearchPlan_4_0-4.0.pdf
334676 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
334676 RR_Budget_1_4-1.4.pdf
334676 RR_SubawardBudget30_1_4-1.4.pdf
334676 PHS398_ModularBudget_1_2-1.2.pdf
334676 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
334676 RR_SF424_5_0-5.0.pdf
334676 PHS398_CoverPageSupplement_5_0-5.0.pdf
334676 RR_OtherProjectInfo_1_4-1.4.pdf
334676 PerformanceSite_4_0-4.0.pdf
334676 RR_KeyPersonExpanded_4_0-4.0.pdf
334676 PHS398_ResearchPlan_4_0-4.0.pdf
334676 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
334676 RR_Budget_3_0-3.0.pdf
334676 RR_SubawardBudget30_3_0-3.0.pdf
334676 PHS398_ModularBudget_1_2-1.2.pdf
334676 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
